Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.2810 -0.0016 (-0.57%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2024 Numbers, Corporate Update Conference Call

August 09, 2023

Via Investor Brand Network

Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023

August 08, 2023

From Vistagen

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 08, 2023

Via Benzinga

What's Going On With VistaGen Therapeutics Stock? ↗

August 08, 2023

VistaGen Therapeutics Inc (NASDAQ: VTGN) shares are trading lower Tuesday.

Via Benzinga

VistaGen Therapeutics Inc. (NASDAQ: VTGN) Near the Top of Equities by Percentage Gain on 8/7

August 07, 2023

Via Investor Brand Network

Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

August 08, 2023

Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 08, 2023

Via Benzinga

Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today? ↗

August 07, 2023

Vistagen Therapeutics has reported positive Phase 3 trial results for a social anxiety treatment. VTGN stock is skyrocketing as a result.

Via InvestorPlace

Dow Gains 1%; Tabula Rasa HealthCare Shares Spike Higher ↗

August 07, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 350 points on Monday. The Dow traded up 1.02% to 35,423.19 while the NASDAQ rose 0.24% to 13,942.57. The S&P...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 07, 2023

Via Benzinga

Crude Oil Down Over 1%; Henry Schein Earnings Top Views ↗

August 07, 2023

U.S. stocks were higher midway through trading, with the Dow Jones gaining more than 300 points on Monday. The Dow traded up 0.88% to 35,374.41 while the NASDAQ rose 0.12% to 13,925.71. The S&P 500,...

Via Benzinga

Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 07, 2023

Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of...

Via Benzinga

InvestorNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Fasedienol Demonstrates Potential to Transform Treatment Landscape for Social Anxiety Disorder

August 07, 2023

Via Investor Brand Network

Elanco Animal Health, Sovos Brands, Veritiv, Graham And Other Big Stocks Moving Higher On Monday ↗

August 07, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Dow Jumps 250 Points; Tyson Foods Posts Downbeat Results ↗

August 07, 2023

U.S. stocks were higher this morning, with the Dow Jones gaining more than 250 points on Monday. Following the market opening Monday, the Dow traded up 0.77% to 35,334.81 while the NASDAQ rose 0.42% to...

Via Benzinga

Vistagen's Big Breakthrough: Says Single Administration Of Nasal Spray Candidate Can Potentially Reduce Anxiety Symptoms, Stock Skyrockets ↗

August 07, 2023

Vistagen Therapeutics Inc (NASDAQ: VTGN) released topline results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol (PH94B) nasal spray in adults...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 07, 2023

Via Benzinga

Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

August 07, 2023

From Vistagen

Via Business Wire

VistaGen's New Preclinical Depression Treatment Study: Itruvone Nasal Spray Limits Systemic Exposure, Shows Promise ↗

July 17, 2023

Vistagen Inc (NASDAQ: VTGN) revealed a new mechanism of action data from a preclinical tissue distribution

Via Benzinga

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces New Preclinical Data Further Demonstrating Unique Mechanism of Action for Itruvone (‘PH10’)

July 17, 2023

Via Investor Brand Network

Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain

July 17, 2023

From Vistagen

Via Business Wire

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Receipt from CIPO of Notice of Allowance for Dyskinesia Treatment

July 14, 2023

Via Investor Brand Network

Topics Intellectual Property

Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

July 13, 2023

From Vistagen

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 07, 2023

Via Benzinga

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2023 Financial Report, Corporate Update

June 29, 2023

Via Investor Brand Network

Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results

June 28, 2023

From Vistagen

Via Business Wire

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Scheduled Conference Call to Report on FY 2023 Financial Numbers

June 28, 2023

Via Investor Brand Network

Earnings Scheduled For June 28, 2023 ↗

June 28, 2023

Companies Reporting Before The Bell • General Mills (NYSE:GIS) is estimated to report quarterly earnings at $1.07 per share on revenue of $5.17 billion.

Via Benzinga

Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023

June 27, 2023

From Vistagen

Via Business Wire

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Compliance with Nasdaq Listing Requirements

June 23, 2023

Via Investor Brand Network

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.